Loading
A phase 1 trial of Eganelisib run by Infinity Pharmaceuticals, Inc., of unknown status on the registry.
A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 is a phase 1 interventional study registered as NCT02637531 by Infinity Pharmaceuticals, Inc., with 219 participants planned, started 2015-12. Conditions recorded: Advanced Solid Tumors (Part A/B/C/D), Non-small Cell Lung Cancer (Part E), Melanoma (Part E), Squamous Cell Cancer of the Head and Neck (Part E), Triple Negative Breast Cancer (Part F), Adrenocortical Carcinoma (Part G), Mesothelioma (Part G) and High-circulating Myeloid-derived Suppressor Cells (Part H). Interventions recorded: IPI-549 (eganelisib) and Nivolumab.
Shares Stelexis BioSciences, Eganelisib, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Stelexis BioSciences, Eganelisib and the tag pipeline.
Shares Stelexis BioSciences, Eganelisib and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Melanoma, Metastatic cancer (cancer that has spread), Non-small-cell lung cancer and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Triple-negative breast cancer (TNBC), Non-small-cell lung cancer and the tag pipeline.
Shares Melanoma, Triple-negative breast cancer (TNBC), Metastatic cancer (cancer that has spread), Non-small-cell lung cancer and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Metastatic cancer (cancer that has spread), Non-small-cell lung cancer and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Triple-negative breast cancer (TNBC), Non-small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/